FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or HER2-ultralow Breast Cancer By Ogkologos - March 6, 2025 468 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DESTINY-Breast06 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation... July 9, 2025 Complete Cancer Prevalence in Europe in 2020 Reveals an Increased Proportion... February 1, 2024 EMA Recommends Granting a Marketing Authorisation for Biosimilar Denosumab April 16, 2024 What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials December 6, 2023 Load more HOT NEWS Efficacy and Safety of Adjuvant Pertuzumab, Trastuzumab and Chemotherapy After 6... ESMO Calls for Oncology-Specific Safeguards in the EU Critical Medicines Act Sugar and cancer – what you need to know Loving Yourself
